23 Jan Cellistic
Andy Holt, Chief Commercial Officer
April 13 | 10:30am | Dark Horse Consulting Ballroom
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. Our focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development position us to be the partner of choice for innovative cell therapy developers to commercialize novel advanced therapies. Leveraging more than a decade of Ncardia’s scientific and technical iPSC knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC-based cells that deliver quality products at scale.